This article was originally published in The Tan Sheet
Advertising for BIE Health Products' GHR "human-growth hormone 'releaser'" has been referred to the Federal Trade Commission and FDA since the firm declined to adequately participate in the National Advertising Division's self-regulatory forum, NAD states July 17. The Council of Better Business Bureaus division identified suspect claims for GHR such as "reversal of many degenerative disease symptoms" and "increased bone density" through its routine and ongoing monitoring program. Although BEI agreed to "provide evidence for review under criteria dictated by BIE," the firm's refusal to participate in NAD's forum according to established procedures leads NAD to refer the ad claims to FTC and FDA for "possible law enforcement action," NAD says...
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.